Company research
Assertio Holdings, Inc.
CIK 1808665Updated Sep 27, 2026
Securities
Historical securities (1)
ASRT · NASDAQ · equity · closed Jun 15, 2026Name history
Assertio Therapeutics, Inc · through May 10, 2019DEPOMED INC · through May 26, 2016DEPOMED INC · through May 26, 2016
ASRT price & chart
Historical security
This listing closed Jun 15, 2026. Live provider charts are shown only for current listings.
About the company
Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit www.assertiotx.com.
In the news
Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders ↗
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025 News provided by Berger Montague Sep 23, 2025, 08:36 ET Share this article Share to X Share this article Share to X PHIL ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 266,970,000Source | 284,732,000Source | 286,419,000Source | 413,913,000Source |
| Property, Plant and Equipment, NetUSD | 444,000Source | 586,000Source | 770,000Source | 744,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 48,908,000Source | 80,471,000Source | 111,332,000Source | 197,996,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,229,000Source | 50,588,000Source | 73,441,000Source | 64,941,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 120,110,000Source | 54,120,000Source | 47,663,000Source | 45,357,000Source |
| Inventory, NetUSD | 24,120,000Source | 38,308,000Source | 37,686,000Source | 13,696,000Source |
| Assets, CurrentUSD | 216,646,000Source | 202,549,000Source | 171,062,000Source | 132,262,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,011,000Source | 10,067,000Source | 12,272,000Source | 8,268,000Source |
| Operating Lease, Right-of-Use AssetUSD | 971,000Source | 1,125,000Source | 1,269,000Source | 137,000Source |
| Other Assets, NoncurrentUSD | 972,000Source | 1,126,000Source | 3,255,000Source | 2,709,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 173,018,000Source | 163,651,000Source | 148,416,000Source | 188,188,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 9,000Source | 9,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 797,450,000Source | 794,196,000Source | 789,537,000Source | 545,321,000Source |
| Retained Earnings (Accumulated Deficit)USD | -703,499,000Source | -673,124,000Source | -651,543,000Source | -319,601,000Source |
| Stockholders' Equity Attributable to ParentUSD | 93,952,000Source | 121,081,000Source | 138,003,000Source | 225,725,000Source |
| Liabilities and EquityUSD | 266,970,000Source | 284,732,000Source | 286,419,000Source | 413,913,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 127,513,000Source | 114,688,000Source | 93,443,000Source | 95,316,000Source |
| Operating Lease, Liability, CurrentUSD | 240,000Source | 331,000Source | 928,000Source | 401,000Source |
| Accounts Payable, CurrentUSD | 9,014,000Source | 14,736,000Source | 13,439,000Source | 5,991,000Source |
| Operating Lease, Liability, NoncurrentUSD | 889,000Source | 1,122,000Source | 1,470,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | 6,381,000Source | 10,150,000Source | 16,459,000Source | 4,269,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 14,282,000Source | 18,847,000Source | 18,213,000Source | 12,181,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 0Source | 470,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 39,124,000Source | 38,813,000Source | 38,514,000Source | 66,403,000Source |
| Short-term InvestmentsUSD | 53,176,000Source | 49,466,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 109,625,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 30,005,000Source | 25,829,000Source | 28,229,000Source | 33,396,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,454,000Source | 5,009,000Source | 9,158,000Source | 7,504,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 65,990,000Source | 6,457,000Source | -48,669,000Source | 996,000Source |
| Increase (Decrease) in InventoriesUSD | -9,678,000Source | 9,583,000Source | 4,973,000Source | 6,593,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 76,201,000Source | -80,375,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -28,182,000Source | 26,408,000Source | 49,604,000Source | 78,598,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -11,988,000Source | -48,911,000Source | 3,097,000Source | -42,673,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 0Source | 628,000Source | 274,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 189,000Source | 350,000Source | 7,898,000Source | 872,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -189,000Source | -350,000Source | -44,201,000Source | -7,794,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | 0Source | -31,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -40,359,000Source | -22,853,000Source | 8,500,000Source | 28,131,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,229,000Source | 50,588,000Source | 73,441,000Source | 64,941,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,600,000Source | 2,600,000Source | 3,651,000Source | 7,752,000Source |
| Income Taxes Paid, NetUSD | -142,000Source | 1,594,000Source | 4,031,000Source | 6,913,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,500,000Source | — | — | — |
| Amortization of Debt Issuance CostsUSD | 475,000Source | 439,000Source | 455,000Source | — |
| Amortization of Intangible AssetsUSD | 29,863,000Source | 25,644,000Source | 27,527,000Source | 32,608,000Source |
| DepreciationUSD | 100,000Source | 200,000Source | 700,000Source | 800,000Source |
| Gain (Loss) on Disposition of BusinessUSD | -8,174,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 1,046,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | 5,217,000Source | 279,639,000Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 1,700,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 435,000Source | 52,000Source | 77,888,000Source | -78,459,000Source |
| InterestExpenseNonoperatingUSD | 3,075,000Source | — | — | — |
| Inventory Write-downUSD | 4,510,000Source | — | — | — |
| Investment Income, InterestUSD | 2,665,000Source | 3,221,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -30,375,000Source | -21,581,000Source | -331,942,000Source | 109,625,000Source |
| Nonoperating Income (Expense)USD | -8,404,000Source | 2,947,000Source | -10,518,000Source | -8,239,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,780,000Source | -278,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 7,020,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 200,000Source | 34,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 118,713,000Source | 124,961,000Source | 152,069,000Source | 156,234,000Source |
| Selling, General and Administrative ExpenseUSD | 69,000,000Source | 75,051,000Source | 78,638,000Source | 46,786,000Source |
| Operating Income (Loss)USD | -21,536,000Source | -24,476,000Source | -243,536,000Source | 39,405,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,780,000Source | -278,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -29,940,000Source | -21,529,000Source | -254,054,000Source | 31,166,000Source |
| Income Tax Expense (Benefit)USD | 435,000Source | 52,000Source | 77,888,000Source | -78,459,000Source |
| Net Income (Loss) Attributable to ParentUSD | -30,375,000Source | -21,581,000Source | -331,942,000Source | 109,625,000Source |
| Earnings Per Share, BasicUSD per share | -4.74Source | -0.23Source | -4.67Source | 2.33Source |
| Earnings Per Share, DilutedUSD per share | -4.74Source | -0.23Source | -4.67Source | 2.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 6,403,000Source | 95,271,000Source | 71,031,000Source | 47,004,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 6,403,000Source | 95,271,000Source | 71,031,000Source | 54,669,000Source |
| Interest Expense (non-operating)USD | 3,075,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 29,863,000Source | 25,644,000Source | 27,527,000Source | 32,608,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | 35,383,000Source | 39,227,000Source | 27,020,000Source | 18,748,000Source |
| Costs and ExpensesUSD | 140,249,000Source | 149,437,000Source | 395,605,000Source | 116,829,000Source |
| Current Income Tax Expense (Benefit)USD | 435,000Source | 52,000Source | 1,687,000Source | 1,916,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -29,940,000Source | -21,529,000Source | -254,054,000Source | 30,734,000Source |
| Interest ExpenseUSD | — | — | — | 7,961,000Source |
| Interest Expense, DebtUSD | — | 0Source | 9,918,000Source | 7,961,000Source |
| Investment Income, InterestUSD | 2,665,000Source | 3,221,000Source | — | — |
| Nonoperating Income (Expense)USD | -8,404,000Source | 2,947,000Source | -10,518,000Source | -8,239,000Source |
| Research and Development ExpenseUSD | 1,690,000Source | 3,822,000Source | 2,843,000Source | — |
Filing attachments
tm2617883d1_ex4-1.htm · 8-K · 2026-06-16
EX-4.1 5 tm2617883d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (“Supplemental Indenture”), dated as of June 16, 2026, between ASSERTIO HOLDINGS, INC., a Delaware corporation (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”). RECITALS OF THE COMPANY WHEREAS, the Company and the Trustee are parties to that certain Indenture, dated as of August 25, 2022 (the “Indent…
Read attachment ↗tm2617883d1_ex99-1.htm · 8-K · 2026-06-16
EX-99.1 6 tm2617883d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027 LAKE FOREST, IL, June 16, 2026 - Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful completion of its previously announced merger (the “Merger”) with Zydus Lifesciences Ltd. (“Zydus Lifesciences”) …
Read attachment ↗tm2611405d26_ex99-1.htm · 8-K · 2026-05-13
EX-99.1 3 tm2611405d26_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash All-Cash Tender Offer of $23.50 per share or $166.4 Million Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price LAKE FOREST, IL., May 13, 2026 - Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, following an engagement process outlined under the revis…
Read attachment ↗tm2611405d24_ex99-1.htm · 8-K · 2026-05-08
EX-99.1 2 tm2611405d24_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Assertio and Garda Mutually Agree to Delay Launch of Tender Offer LAKE FOREST, IL - May 8, 2026 - Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May …
Read attachment ↗tm2611405d21_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 2 tm2611405d21_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Privileged & Confidential Prepared at the request of counsel Press Release Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer LAKE FOREST, IL - May 5, 2026 - Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to postpone the commencement of the previously announced tender offer to acquire all…
Read attachment ↗tm2611405d19_ex99-1.htm · 8-K · 2026-05-04
EX-99.1 3 tm2611405d19_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Privileged & Confidential Prepared at the request of counsel Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics Increased All-Cash Tender Offer Price of $21.80 per share - or $153.2 Million New Tender Offer Price Represents 21.1% Premium to Prior Offer LAKE FOREST, Ill., May 4, 2026 - Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Asserti…
Read attachment ↗